Short answer
Cryoport, Inc. (CYRX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $49M (up 7.7% year over year) with net income of −$8M.
Q2 2026 key financials · XBRL
- Revenue
- $49M
- +7.7% YoY · +2.5% QoQ
- Net income
- −$8M
- −107.8% YoY · +21.7% QoQ
- Operating margin
- -20.5%
- Gross margin
- 46.6%
- EPS (diluted)
- −$0.20
- −109.7% YoY · +20.0% QoQ
Source: XBRL data from the Cryoport, Inc. (CYRX) Q2 2026 10-Q on SEC EDGAR. USD.
Cryoport, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability, margin, or net income percentages provided
- Headwinds: supply chain constraints, inflation, tariffs, trade restrictions, foreign exchange, geopolitical conditions
- Outlook references cell and gene therapy expansion, strategic relationships, regulatory approvals, and CRYOPDP divestiture risks
Risk Factors
- No material changes to 2025 Annual Report risk factors
- Carried-forward risks include business, financial-condition, and operating-performance deterioration
- CEO trading plan permits sales of up to 500,000 shares through March 12, 2027
- Director trading plan permits sales of up to 74,379 shares through July 30, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cryoport, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.